PDL Stockholders Get $500 Million, As Promised
This article was originally published in The Pink Sheet Daily
Executive Summary
Troubled biotech spins off R&D, leaves shell to manage royalty income.
You may also be interested in...
One Down, But More Remain: PDL Settles Patent Scrap With Alexion Over Soliris
One-time $25M payout for license ends dispute over royalties for hemoglobinuria therapy.
One Down, But More Remain: PDL Settles Patent Scrap With Alexion Over Soliris
One-time $25M payout for license ends dispute over royalties for hemoglobinuria therapy.
PDL Deal Adds To BMS’ Chips In Multiple Myeloma
Phase I antibody represents novel, targeted approach in a busy space.